L-ORNITHINE L- ASPARTATE( LOLA) VERSUS STANDARD MEDICAL THERAPY (SMT) FOR IMPROVEMENT OF SARCOPENIA IN PATIENTS WITH CIRRHOSIS - A RANDOMIZED OPEN LABEL TRIAL

被引：0

作者：

Najar, Rameez Raja ^{[1
]}

Sahney, Amrish ^{[1
]}

Wadhavan, Manav ^{[1
]}

Ganesan, Prem Kumar ^{[1
]}

Kumar, Ajay ^{[1
]}

Vij, Jc ^{[1
]}

Berry, Neha ^{[1
]}

Reethesh, S. R. ^{[1
]}

Sondhi, Pulkit ^{[1
]}

Ansari, Md Nuruddin ^{[1
]}

机构：

[1] BLK MAX SS Hosp New Delhi, New Delhi, India

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

3055-A

引用

页码：S1373 / S1373

页数：1

共 30 条

[21] SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Andre, T.
Saunders, M. P.
Kanehisa, A.
Gandossi, E.
Fougeray, R.
Causse-Amellal, N.
Falcone, A.
ANNALS OF ONCOLOGY, 2019, 30 : 250 - 250
[22] Simplification to dual therapy (atazanavir/ritonavir plus lamivudine) versus standard triple therapy [atazanavir/ritonavir plus two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Perez-Molina, J. A.
Rubio, R.
Rivero, A.
Pasquau, J.
Suarez-Lozano, I.
Riera, M.
Estebanez, M.
Palacios, R.
Sanz-Moreno, J.
Troya, J.
Marino, A.
Antela, A.
Navarro, J.
Esteban, H.
Moreno, S.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (01) : 246 - 253
[23] STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
Bendell, Johanna C.
Tan, Benjamin R.
Reeves, James Andrew
Xiong, Henry Q.
Laeufle, Rita
Byrtek, Michelle
Sommer, Nicolas
Hurwitz, Herbert
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy
Dent, Rebecca
Cescon, David W.
Bachelot, Thomas
Jung, Kyung Hae
Shao, Zhi-Ming
Saji, Shigehira
Traina, Tiffany A.
Vukovic, Petra
Mapiye, Darlington
Maxwell, Micah
Schmid, Peter
Cortes, Javier
CANCER RESEARCH, 2023, 83 (05)
[25] A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
Galsky, Matt D.
Necchi, Andrea
Sridhar, Srikala S.
Ogawa, Osamu
Angra, Natasha
Hois, Stephan
He, Philip
Ghiorghiu, Dana C.
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[26] A phase Ill, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
Galsky, Matt D.
Necchi, Andrea
Sridhar, Srikala S.
Ogawa, Osamu
Ruscica, Dario
Angra, Natasha
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[27] A phase III, randomized, open-label trial of nivolumab (anti-PD-1) ; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+non-small cell lung cancer (NSCLC)
Carbone, David Paul
Socinski, Mark A.
Chen, Allen C.
Bhagavatheeswaran, Prabhu
Reck, Marlin
Paz-Ares, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[28] A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastroesophageal junction (G/GEJ) cancer
Moehler, Markus H.
Cho, Jae Yong
Kim, Yeul Hong
Kim, Jin Won
Di Bartolomeo, Maria
Ajani, Jaffer A.
Yamaguchi, Kensei
Balogh, Agnes
Kong-Sanchez, Maria Teresa
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] Second-Line or Third-Line Therapy for advanced Renal Cell Cancer after Anti-PD1/L Failure An open-label, randomized Phase-III Trial study of MK-6482 in Combination with Lenvatinib (MK-7902) versus Cabozantinib as Second-Line or Third-Line Therapy in Patients with advanced Renal Cell Cancer who had Disease Progression after prior Anti-PD-1/L1 Therapy (AN 53/20 of AUO, HIF-011)
Rexer, H.
Banek, S.
Doehn, C.
UROLOGE, 2022, 61 (02): : 239 - 240
[30] AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT).
Gridelli, Cesare
Bennouna, Jaafar
De Castro, Javier
Dingemans, Anne-Marie C.
Griesinger, Frank
Grossi, Francesco
Thatcher, Nick
Ohe, Yuichiro
Diego Perez-Moreno, Pablo
Langer, Corey J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 →